Close X
Attorney Spotlight

Find out which two countries Cheryl Palmeri gets the most questions about related to International Trade in today's market? Find out more>


Close X


Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Shannon Wiley Outlines CMS Medicaid Drug Rebate Program Final Rule

AHLA Life Sciences and Regulation, Accreditation, & Payment Practice Groups Alert


February 3, 2016

Bass, Berry & Sims attorney Shannon Wiley outlined the details of the Centers for Medicare & Medicaid Services (CMS) final rule on the Medicaid drug rebate program that goes into effect April 1, 2016. The article focuses on the new rule related to the determination of average manufacturer price (AMP). As stated in the article, "[o]n the issue of AMP calculation, the Final Rule addressed the use of the industry norm 'presumed inclusion' approach versus the proposed 'buildup' approach when calculating sales to wholesalers for drugs distributed to retail community pharmacies."

The full article, "CMS Releases Final AMP Rule," was published by the Life Sciences and Regulation, Accreditation, & Payment Practice Groups of the American Health Lawyers Association (AHLA) on February 1, 2016. The full article is available to members to the AHLA website.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.